07:00 , Sep 1, 2014 |  BioCentury  |  Finance

Exiting Covagen

Terms of Johnson & Johnson 's takeout of Covagen AG are undisclosed, but the antibody platform company's largest investor said the deal is likely one of the biggest this year in terms of both size...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Financial News

Covagen completes venture financing

Covagen AG , Zurich, Switzerland   Business: Inflammation, Cancer, Autoimmune   Date completed: 12/9/13   Type: Venture financing   Raised: Not disclosed   Investors: Gimv; Ascent Biomedical Ventures; Novartis Venture Funds; Edmond de Rothschild Investment...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

Covagen board of directors update

Covagen AG , Zurich, Switzerland   Business: Inflammation   Appointed: Avi Kometz, partner at Ascent Biomedical Ventures; and Karl Naegler, partner at Gimv  ...
01:29 , Dec 10, 2013 |  BC Extra  |  Financial News

Covagen secures $47.1 million in series B

Covagen AG (Zurich, Switzerland) secured CHF42 million ($47.1 million) in a tranched series B round led by new investor Gimv. New investor Ascent Biomedical Ventures also participated, along with existing investors Novartis Venture Fund; Edmond...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Financial News

Coferon completes venture financing

Coferon Inc. , New York, N.Y.   Business: Drug delivery   Date completed: 7/16/12   Type: Venture financing   Raised: $12 million   Investors: Hatteras Venture Partners; MedImmune Ventures; Ascent Biomedical Ventures  ...
00:11 , Jul 17, 2012 |  BC Extra  |  Financial News

Coferon raises $12M in series B

Coferon Inc. (New York, N.Y.) raised $12 million in a series B round from new investors Hatteras Venture Partners; MedImmune Ventures; and Ascent Biomedical Ventures. Coferon uses bioorthogonal linker chemistry to deliver therapeutics that self-assemble...
07:00 , Jul 16, 2012 |  BioCentury  |  Emerging Company Profile

Coferon: Some assembly required

Rather than trying to make ever smaller molecules that retain activity against complex targets, Coferon Inc. is using a bioorthogonal linker technology to deliver two halves of a therapeutic that self-assemble on the target after...
08:00 , Nov 22, 2010 |  BioCentury  |  Finance

Angels in NYC

Angels in NYC The New York Academy of Sciences last week launched the Life Science Angel Network (LSAN). The network is focused on biotechnology, medical devices and healthcare IT. A panel of clinicians, scientists, entrepreneurs...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Financial News

Cara completes venture financing

Cara Therapeutics Inc. , Shelton, Conn.   Business: Neurology   Date completed: 7/21/10   Type: Venture financing   Raised: $15 million   Investors: Rho Ventures; Alta Biopharma; Ascent Biomedical Ventures; Connecticut Innovations; Devon Park Bioventures;...
00:35 , Jul 22, 2010 |  BC Extra  |  Financial News

Cara raises $15 million

Cara Therapeutics Inc. (Shelton, Conn.) raised $15 million in a series D round led by new investor Rho Ventures. Existing investors Alta Biopharma; Ascent Biomedical Ventures; Connecticut Innovations; Devon Park Bioventures; Healthcare Private Equity; Mitsubishi...